New modalities in diabetes treatment.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Type II diabetes management often struggles with adequate hyperglycemia control.
• Newer therapeutic approaches aim to improve glycemic control, including combination therapies.
• Concerns about hyperinsulinemia and atherosclerosis drive interest in therapies that reduce insulin resistance.

Purpose of the Study:

• To evaluate the efficacy of combining insulin with glyburide versus insulin with placebo in non-obese, insulin-requiring type II diabetic patients.
• To assess the impact of combination therapy on glycemic control and beta-cell sensitivity.

Main Methods:

• A double-blinded, placebo-controlled trial involving twenty type II diabetic patients.
• Patients were hospitalized for initial optimization of intermediate-acting insulin therapy.
• Participants were randomly assigned to receive either insulin and glyburide or insulin and placebo, followed by a four-month outpatient period and rehospitalization for assessment.

Main Results:

• The insulin and glyburide group maintained normal fasting serum glucose levels throughout the study.
• The placebo and insulin group showed significantly higher fasting serum glucose levels at four and eight weeks.
• Glycosylated hemoglobin levels increased progressively in the placebo and insulin group, becoming significantly higher than in the insulin and glyburide group by 16 weeks.

Conclusions:

• Combination therapy with insulin and glyburide is effective in achieving and maintaining normal fasting glucose levels in type II diabetic patients.
• This combination therapy demonstrates superior glycemic control compared to insulin therapy alone, as evidenced by glycosylated hemoglobin levels.
• The findings support the use of combined insulin and glyburide therapy for improved management of type II diabetes.